Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Podcast TCTMD Talking Points

DES for Femoropopliteal Disease: IMPERIAL

January 09, 2019

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Caitlin E. Cox

February 13, 2018

Advertisement

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

FDA’s First Take on New Paclitaxel Concerns in CLI

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

DES for Femoropopliteal Disease: IMPERIAL

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content